A Study to Assess Immune Response to Multiple Doses of PF-06881894 or US-Approved Neulasta in Healthy Volunteers

Exclusion Criteria

• •Hematologic laboratory abnormalities (including leukocytosis \[defined as total leukocytes \>11,000/mcL\], leukopenia \[defined as total leukocytes \<4000/mcL\], or neutropenia \[defined as absolute neutrophil count \<1500/mcL\] or thrombocytopenia \[defined as platelet count of \<150,000/mcL\]) or other clinically significant abnormal laboratory evaluations.
• •Lack of adequate hepatic or renal reserve.
• •Any active systemic or immunologic disease or condition.
• •History of biological growth factor exposure.
• •Received live vaccination or exposure to communicable viral diseases within 4 weeks prior to Screening.